YouSigma- the web's most extensive resource for information
$6.99 Domain Names at Network SolutionsĀ®!
Gilead Sciences Inc. (SWOT Analysis)

Go to Home Page

Tell your friend about this WebSite!

Download PDF Version!

“SWOT is an acronym for the internal Strengths and Weaknesses of a firm and the environmental Opportunities and Threats facing that firm. SWOT analysis is a widely used technique through which managers create a quick overview of a company’s strategic situation. The technique is based on the assumption that an effective strategy derives from a sound “fit” between a firm’s internal resources (strengths and weaknesses) and its external situation (opportunities and threats). A good fit maximizes a firm’s strengths and opportunities and minimizes its weaknesses and threats. Accurately applied, this simple assumption has powerful implications for the design of a successful strategy.”

Gilead Sciences Inc.

Gilead Sciences (Gilead) is a research-based biopharmaceutical company engaged in discovering, developing and commercializing medicines in areas of unmet medical need. It primarily focuses on HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. The company primarily operates in North America, Europe and Australia. It is headquartered in Foster City, California and employs 3,441 people.

Strengths, Weaknesses, Opportunities and Threats (SWOT)

Location of Factor

TYPE OF FACTOR

Favorable

Unfavorable

Internal

Strengths

  • A leading position in the HIV market, driven by three products: Viread, Truvada, and key growth driver, Atripla
  • Strong operating profit performance

Weaknesses

  • Despite diversification into cardiovascular, Gilead’s portfolio is still heavily reliant on one disease area: HIV

External

Opportunities

  • Letairis sales growth and darusentan offering therapy area diversity
  • Elvitegravir promising launch candidate which should add to dominant HIV franchise as an add-on therapy, hence limiting sales cannibalization
  • RoW growth

Threats

  • By operating as a 100% small molecule player, Gilead is open to extensive generic threat.
underline
About YouSigma Please Donate Using PayPal, to help us Develop Content
Copyright and Disclaimer
Loading
underline
underline
Try a free sample Destiny Reading! Executive Openings! $80,000 to $500,000+
"Gilead Sciences Inc. (SWOT Analysis)";